Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Predictability of Drug Pricing Must Be Ensured: EFPIA Japan Director General
April 22, 2022
- Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
April 12, 2022
- FPMAJ Looks into Impact of Shanghai COVID-19 Lockdown
April 11, 2022
- Asian Pharma Groups to Boost Drug Discovery Collab via RWD Use
April 7, 2022
- Drug Damage Watchdog Calls for Temporary Suspension of Lagevrio Use
April 6, 2022
- JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
April 5, 2022
- Stop Avigan Stockpiling, Revoke Flu Approval: Drug Damage Watchdog
April 5, 2022
- JPMA to Push Innovation Cycle, Ponder Next-Gen Pricing System: FY2022 Project Plan
April 5, 2022
- Policy Veterans’ Group Proposes Free Pricing, Chuikyo Re-Pricing Few Years Later
April 4, 2022
- Generic Use Rate Treads Water at 79.3% in October-December: JGA
April 4, 2022
- FPMAJ Poll Finds 65% Self-Inspection Rate for “Stable Supply Medicines”
March 28, 2022
- FPMAJ Hammers Out FY2022 Project Plans, Revs Up for Off-Year Revision Debate
March 28, 2022
- FPMAJ Begins Survey on Risk of Mineral Resource Shortages amid Ukraine War
March 28, 2022
- JGA to Employ 3rd Party Auditor on Trial Basis to Ensure Manufacturing Compliance
March 28, 2022
- Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
March 25, 2022
- FPMAJ Launches Taskforce to Conduct Supply Surveys for 130 APIs
March 25, 2022
- Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
March 22, 2022
- FPMAJ Should Take Lead to Address Drug Supply Issues: JMA Chief
March 17, 2022
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Drug Makers Launch Digital Health Advocacy Group, Mitsubishi Tanabe Exec Serves as Head
March 15, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…